Type 2 inflammation in asthma and other airway diseases

Jorge Maspero1, Yochai Adir2, Mona Al-Ahmad3, Carlos A. Celis-Preciado4,5, Federico D. Colodenco6, Pedro Giavina-Bianchi7, Hani Lababidi8, Olivier Ledanois9, Bassam Mahoub10,11, Diahn-Warng Perng12, Juan C. Vazquez13 and Arzu Yorgancioglu14

1Fundacion CIDEA (Centro de Investigacion de Enfermedades Alergicas y Respiratorias), University of Buenos Aires, Buenos Aires, Argentina. 2Pulmonary Division, Lady Davis Carmel Medical Center, Faculty of Medicine, The Technion, Institute of Technology, Haifa, Israel. 3Microbiology Dept, Faculty of Medicine, Kuwait University, Kuwait City, Kuwait. 4Pulmonary Unit, Internal Medicine Department, Hospital Universitario San Ignacio, Bogota, Colombia. 5Faculty of Medicine, Pontificia Universidad Javeriana, Bogota, Colombia. 6Pulmonology, Hospital De Rehabilitacion Respiratoria Maria Ferrer, Buenos Aires, Argentina. 7Clinical Immunology and Allergy Division, University of Sao Paulo, Sao Paulo, Brazil. 8King Fahad Medical City, Riyadh, Saudi Arabia. 9Sanofi Genzyme, Paris, France. 10Dept of Pulmonary Medicine and Allergy and Sleep Medicine, Rashid Hospital, Dubai, United Arab Emirates. 11Dept of Medicine and Chest Disease, University of Sharjah, Sharjah, United Arab Emirates. 12Taipei Veterans General Hospital, Taipei, Taiwan. 13Instituto Nacional de Enfermedades Respiratorias, Mexico City, Mexico. 14Dept of Chest Diseases, Faculty of Medicine, Manisa Celal Bayar University, Manisa, Turkey.

Corresponding author: Jorge Maspero (jorge.maspero@fundacioncidea.org.ar)

Abstract

Chronic inflammatory airway diseases, including asthma, chronic rhinosinusitis, eosinophilic COPD and allergic rhinitis are a global health concern. Despite the coexistence of these diseases and their common pathophysiology, they are often managed independently, resulting in poor asthma control, continued symptoms and poor quality of life. Understanding disease pathophysiology is important for best treatment practice, reduced disease burden and improved patient outcomes.

The pathophysiology of type 2 inflammation is driven by both the innate immune system triggered by pollutants, viral or fungal infections involving type 2 innate lymphoid cells (ILC2) and the adaptive immune system, triggered by contact with an allergen involving type 2 T-helper (Th2) cells. Both ILC2 and Th2 cells produce the type-2 cytokines (interleukin (IL)-4, IL-5 and IL-13), each with several roles in the inflammation cascade. IL-4 and IL-13 cause B-cell class switching and IgE production, release of pro-inflammatory mediators, barrier disruption and tissue remodelling. In addition, IL-13 causes goblet-cell hyperplasia and mucus production. All three interleukins are involved in trafficking eosinophils to tissues, producing clinical symptoms characteristic of chronic inflammatory airway diseases.

Asthma is a heterogeneous disease; therefore, identification of biomarkers and early targeted treatment is critical for patients inadequately managed by inhaled corticosteroids and long-acting β-agonists alone. The Global Initiative for Asthma guidelines recommend add-on biological (anti IgE, IL-5/5R, IL-4R) treatments for those not responding to standard of care. Targeted therapies, including omalizumab, mepolizumab, reslizumab, benralizumab, dupilumab and tezepelumab, were developed on current understanding of the pathophysiology of type 2 inflammation. These therapies offer hope for improved management of type 2 inflammatory airway diseases.
conditions are often managed as single entities, yet their coexistence is common and linked with a shared pathological mechanism. People with allergic asthma can commonly present with allergic rhinitis, and patients with rhinosinusitis with nasal polyps often have comorbid asthma [4]. These comorbidities are associated with overtreatment of asthma with high-dose inhaled corticosteroids (ICS) and poor asthma control, with up to 10% of patients experiencing severe exacerbations, impairment of lung function and quality of life (QoL), and associated healthcare costs [5–7], despite receiving high doses of oral corticosteroids (OCS) [8, 9].

Comprising four component characteristics, including bronchoconstriction, airway inflammation, airway hyperresponsiveness and chronic remodelling of airways, our understanding of the inflammatory mechanisms and immune cell interplay on these components is essential for the development of future treatments for type 2 asthma and comorbidities. Given their frequency, this article focuses on the burden, underlying pathophysiology and management of type 2 inflammation associated with upper and lower airway diseases.

Epidemiology

Asthma is a complex disease caused by both environmental and genetic factors, and is characterised by chronic wheezing and airflow obstruction, which occurs because of inflammation in the airways of the lungs [10]. Triggered by contact with an allergen, atopic asthma is the most common form of asthma, affecting 70–90% of children and ∼50% of adult patients with asthma [11]. The prevalence of atopic diseases is increasing, with allergic asthma, along with atopic dermatitis and allergic rhinitis being described as the milestones of an “atopic march” [12]. Chronic inflammatory airway diseases such as asthma, CRSwNP, COPD with type 2 inflammation, and allergic rhinitis, are prevalent and represent a serious global health concern, creating a substantial clinical and economic burden [13].

Asthma affects 339 million people worldwide [14] and, in 2016, resulted in ∼420 000 deaths [15]. The prevalence of CRSwNP, measured using a patient questionnaire, is estimated at ∼1.1–4.3%, and increases with age [16]. Approximately 15–37% of patients with COPD have persistent blood eosinophils >2%, which may indicate presence of type 2 inflammation [17, 18]. The prevalence of allergic rhinitis varies widely, from 1.6% to 54% across the world [19]. These patients often have evidence of type 2 inflammation, affecting up to 51% of patients with uncontrolled asthma, 55–70% of patients with severe asthma [20–22], 80% of patients with CRSwNP [23, 24], 49% of patients with CRSsNP [25], 15–37% of patients with COPD [17] and 100% of patients with allergic rhinitis (table 1) [19]. Accordingly, type 2 inflammation is responsible of a number of airway diseases that often coexist together.

Type 2 inflammatory airway diseases are common and represent a substantial clinical burden, with debilitating symptoms, reduced QoL and work productivity [44–47]. The frequent systemic corticosteroid use can lead to increased risk of related adverse effects [26, 48, 49], as well as the substantial burden of comorbid type 2 inflammatory diseases [47, 50–53].

Burden of disease

Asthma

Despite access to ICS and long-acting β-agonist (LABA) combination therapy, patients with uncontrolled asthma frequently suffer from poorly controlled comorbidities as well. These patients have impaired lung function, associated with higher risk of asthma exacerbations, further worsening of their type 2 comorbidities. Asthma and severe CRSwNP are frequently associated with other coexisting type 2 inflammatory diseases such as nonsteroidal anti-inflammatory drug-exacerbated respiratory disease (NSAID-ERD), aspirin-exacerbated respiratory disease (AERD), allergic rhinitis, eosinophilic oesophagitis, atopic dermatitis and type 2 eosinophilic COPD [26–29].

Poorly controlled asthma symptoms in patients treated with prescription medicines are common, and affect between 40% and 54% of adults with asthma in the United States [5, 54]. Patients with poorly controlled asthma have significantly reduced health-related QoL, greater overall work impairment and higher healthcare resource utilisation than those with well-controlled asthma [5, 54, 55]. Moreover, patients with very poorly controlled asthma have been shown to incur more than twice the indirect costs and one and a half times the direct healthcare costs compared with those incurred for well-controlled patients [5]. Patients with well-controlled asthma have been reported to have better physical and mental health; fewer emergency room visits, hospitalisation days and medical provider visits; and lower levels of overall work productivity loss and activity impairment [55]. Although the cost of treating asthma is significant, with an estimated USD 18 billion being spent in the United States alone, about half of patients with asthma continue to be poorly controlled with ICS and LABA treatments [5]. Asthma exacerbations are associated with significant
morbidity and account for a substantial proportion of asthma-related costs. Therefore, effective management of asthma and related comorbidities, prevention of subsequent asthma exacerbations and reduction of asthma severity are important to ensure reduction of healthcare costs as well as improvement in the QoL of patients with asthma [56, 57].

Extrapulmonary comorbidities contribute substantially to poor asthma control and a heightened disease burden. Guidelines state that patients with poorly controlled asthma should have a diagnosis confirmed, together with addressing comorbidities before phenotyping the pattern of inflammation [58]. Frequent asthma exacerbations are significantly associated with severe nasal sinusitis, chronic rhinosinusitis, psychological dysfunction, bronchiectasis, gastro-oesophageal reflux, obstructive sleep apnoea, vocal cord dysfunction, obesity, dysfunctional breathing and anxiety/depression [57, 59–65].

Allergic rhinitis and chronic rhinosinusitis/CRSwNP

Allergic rhinitis and chronic rhinosinusitis are characterised by inflammation and irritation in the nasal cavities following allergen exposure and are common in patients with asthma, affecting 55–60% and 22–45% of patients, respectively [30, 59, 63, 66, 67]. Indeed, computed tomography has shown that sinusitis may be present in 84% of patients with asthma [68]. Likewise, the increased prevalence of nasal polyps has been associated with asthma severity [69].

Chronic rhinosinusitis is a substantially heterogeneous disease, with patients commonly divided into two subgroups, those with nasal polyps (CRSwNP) and those without nasal polyps (CRSsNP). Although both forms of disease are driven by different inflammatory mechanisms [70, 71], many CRSsNPs can be eosinophilic or have high type 2 inflammation [16]. Patients with CRSwNP are particularly prone to developing asthma, with incidence up to 70%, depending on the degree of type 2 inflammation [72]. Patients with chronic rhinosinusitis have inflammation of the sinonasal mucosa, which results in nasal obstruction, facial pressure or pain, loss of smell and poor drainage lasting for >12 weeks. The surgical and medical management of chronic rhinosinusitis represents a large cost burden, and nasal polyp growth is present in 1–4% of the population of the United States [2, 70]. Notably, patients with CRSwNP may suffer from this condition for decades [72, 73]. In Europe and the United States, the majority of patients with CRSwNP have significant eosinophilic infiltration and elevated levels of IgE in their nasal polyp tissue [2]. Likewise, higher levels of eosinophils in the serum and sputum in these conditions suggest a close relationship between asthma and chronic rhinosinusitis [68].

### TABLE 1 Airway diseases driven by type 2 inflammation [17–24, 26–41]

| Disease | Evidence of type 2 inflammation | Proportion of type 2 patients | Comorbid disease prevalence |
|---------|---------------------------------|------------------------------|-----------------------------|
| Asthma  | Elevated serum IgE             | 51%                          | + CRSwNP 30–50%             |
|        | Elevated serum eosinophils      |                              | + Allergic rhinitis >80%    |
|         |                                 |                              | + COPD [33] ~13%            |
|         |                                 |                              | + NSAID-ERD/AERD ~7%        |
| Severe  | Elevated sputum eosinophils     | 55–70%                       |                             |
|         | Expression of IL-13-inducible   |                              |                             |
|         | genes in sputum cells           |                              |                             |
| Diffuse | Elevated blood eosinophils or F<sub>ENO</sub> | 71%                          |                             |
| CRSwNP  | Elevated CLC and IL-13 gene     | ~80%                         | + Asthma 50%                |
|         | expression                      |                              | + Allergic rhinitis ~75%    |
|         | Elevated IL-5 and Th2 gene      |                              | + NSAID-ERD/AERD ~10–20%   |
| COPD    | Persistent blood eosinophils ≥300| 15–37%                       | A subset may also present   |
|         | cells·µL<sup>−1</sup> or ≥2%    |                              | with asthma [33]            |
|         |                                 |                              | + Allergic rhinitis ~7%     |
| Allergic rhinitis | IgE-mediated disease driven by type 2 | 100%                         | Comorbid asthma [37] 19–38% |
|         | inflammation [10, 37, 38]       |                              | Comorbid CRS [36] ~67%     |

ICS: inhaled corticosteroids; CRSwNP: chronic rhinosinusitis with nasal polyps; NSAID-ERD: nonsteroidal anti-inflammatory drug-exacerbated respiratory disease; AERD: aspirin-exacerbated respiratory disease; IL: interleukin; Th2: type 2 T-helper; F<sub>ENO</sub>: exhaled nitric oxide fraction; CLC: Charcot–Leyden crystals; CRS: chronic rhinosinusitis.
Asthma and associated type 2 inflammatory airway diseases

Type 2 inflammatory airway diseases, such as asthma, CRSwNP, NSAID-ERD/AERD, eosinophilic COPD and allergic rhinitis often coexist in the same patient, and are driven by a similar underlying type 2 pathophysiology [31]. The risk of asthma symptoms increases with increasing presence of CRSwNP [74] along with the increased likelihood of poor asthma control [75, 76]. Likewise, the presence of a comorbid type 2 inflammatory disease increases the severity and clinical burden of CRSwNP, with disease severity being significantly greater in patients with CRSwNP and asthma versus those with CRSwNP alone [53]. The presence of a comorbid type 2 inflammatory disease has also been associated with an increased risk of recurrence of nasal polyps post-surgery in patients with CRSwNP [77].

The coexistence of type 2 inflammatory diseases is associated with greater decline in lung function and clinical outcomes in patients with asthma. A 5-year study of patients with recently diagnosed adult-onset asthma showed that the presence of comorbid nasal polyps was significantly associated with a greater decline in post-bronchodilator forced expiratory volume in 1 s (FEV1) per year [78]. Moreover, comorbid disease has been shown to increase disease burden in patients whose asthma is driven by type 2 inflammation, with the presence of rhinitis, nasal polyps or atopic dermatitis as independent predictors for future asthma exacerbations [79].

Both persistent uncontrolled asthma and CRSwNP contribute to the burden of disease and are common causes of sleep disturbance and fatigue. These conditions have been shown to lead to decreased daytime functioning and reduced QoL [45, 80], as well as having negative impacts on both physical and mental health [47, 81–83]. The impact of these diseases on work productivity and absenteeism has also been shown to result in substantial indirect costs. Almost half of CRSwNP patients awaiting surgery experiencing reduced productivity and a 40–60% overall work impairment in asthma patients despite receiving LABA or ICS treatment. Similarly, a study of >8000 asthma patients with comorbid COPD showed a significantly increased likelihood of severe exacerbations of asthma and COPD, versus healthy nonsmoker controls, with greater annual decline in FEV1 versus asthma or COPD alone [84].

Severe uncontrolled asthma or acute episodes of CRSwNP are frequently treated with OCS. However, this can contribute to the short- and long-term burden of disease. Short-term effects include mood and sleep disturbances, while long-term consequences include osteoporosis, gastrointestinal bleeds, type 2 diabetes, obesity, cataracts and glaucoma [1, 85]. All these conditions have been shown to contribute significantly to patients’ health concerns [86]. Moreover, the healthcare cost of OCS-related side-effects is substantial. Asthma patients with comorbid disease while on OCS generate twice as much healthcare cost compared with nonasthmatic patients [87]. Similarly, patients with CRSwNP taking OCS have higher total healthcare costs compared with those not taking OCS [88]. A systematic literature review over three decades of research has also shown a higher clinical and economic burden in patients with allergic rhinitis and asthma results, with a 1.2- to 2.1-fold increase in annual costs for these patients [89]. Similar results from a United States-based study showed substantially greater healthcare utilisation among patients with both asthma and COPD versus those with asthma or COPD alone, with medical service costs being five times greater in this group than in patients with asthma alone [89].

Type 2 inflammation: pathophysiology

Type 2 inflammation is driven by both the adaptive and innate arms of the immune system and underpins the pathophysiology of several chronic upper and lower airway diseases, including asthma, COPD, CRSwNP and allergic rhinitis [90–92]. Type 2 inflammation is driven by Th2 cells and group 2 innate lymphoid cells (ILC2), which produce the type 2 cytokines, including interleukin (IL)-4, IL-5 and IL-13, as well as other inflammatory mediators (tables 2 and 3) [31, 100–102]. Type 2 cytokines have a range of roles in the pathophysiology of type 2 inflammatory airway diseases. IL-5 plays a pivotal role in the differentiation and maturation of IL-5Rα+ eosinophil progenitors in the bone marrow, as well as their mobilisation and survival. In addition, IL-5 supports the development of other type 2 cells, including mast cells and basophils [103]. IL-4 and IL-13 both play a role in B-cell class switching and IgE production, leading to the degranulation of basophils and mast cells and subsequent release of pro-inflammatory mediators as well as barrier disruption and tissue remodelling [31, 91]. IL-13 is involved in goblet-cell hyperplasia and mucus production [31, 91], as well as smooth muscle contractility and hyperplasia [104]. Moreover, IL-13-mediated damage to the epithelial barriers is also associated with the development of mucus plugs as a consequence of mucus production [104].

IL-4, IL-13 and IL-5 are all involved in trafficking of eosinophils to tissues (figure 1) [3, 31, 105–107]. These common pathophysiological effects, driven by type 2 inflammation, manifest as clinical symptoms, including nasal polyps, loss of smell, and nasal obstruction in CRSwNP [3], and impaired lung function,
wheezing, shortness of breath, chest tightness and coughing in asthma [1]. The key and central cytokines for type 2 airway diseases include IL-4 and IL-13. IL-4 upregulates differentiation of naïve Th0 cells into Th2 cells, which produce IL-4, IL-13 and IL-5, thus creating a cyclical effect [31]. IL-4, IL-5 and IL-13 also induce chemokines (i.e. eotaxin-3, thymus- and activation-regulated chemokine) and vascular cell adhesion molecule 1, which promote migration and trafficking of inflammatory cells, including eosinophils, to the site of inflammation [3, 31]. Eosinophils are activated by IL-5 and are recruited to the airway directly or indirectly by IL-4, IL-13 and IL-5 [31].

Type 2 inflammation in asthma

More specific to asthma, IL-13 has effects on goblet and airway smooth muscle cells, which impact mucus secretion, smooth muscle contractility and basement membrane thickening [31]. Moreover, in asthma, along with the production of mucus, IL-13 facilitates airway obstruction by tethering to mucus-producing cells in the epithelium and impairing mucociliary transport, identified by the expression of the mucin 5AC (MUC5AC) protein, which is considered to be a marker of airway goblet cells and mucus hypersecretion [108], leading to the development of mucosal plugs. Nitric oxide production is also upregulated by IL-13 in asthma [109].

Type 2 inflammation in nasal polyposis

In patients with CRSwNP, an increased inflammatory response results from an innate immune function, causing defects in the nasal epithelial barrier, with subsequent reduced secretion of innate host defence

---

### TABLE 2

| **IL-4** | **IL-13** | **IL-5** |
|----------|-----------|----------|
| Th2 cell differentiation | Goblet cell hyperplasia | Eosinophil differentiation and survival |
| Collagen deposition | Smooth muscle proliferation | Increased contractility |
| Smooth muscle proliferation | Neuroimmune dysfunction | Hyperresponsiveness |
| B-cell isotype switching and IgE production; mast cell and basophil degranulation | Mast cell activation and trafficking to tissue | Mast cell activation and trafficking to tissue |
| Increased contractility | Fibrosis and airway remodelling | Fibrosis and airway remodelling |
| Hyperresponsiveness | Epithelial barrier dysfunction and microbiome imbalance | Epithelial barrier dysfunction and microbiome imbalance |
| TARC-induced migration of Th2 cells | Activation of macrophages to M2 type | Activation of macrophages to M2 type |
| Eosinophil recruitment and trafficking to tissue | Eosinophil recruitment and trafficking to tissue | Eosinophil recruitment and trafficking to tissue |

Th2: type 2 T-helper; TARC: thymus and activation-regulated chemokine.

---

### TABLE 3

| **Asthma (IL-4, IL-13, IL-5)** | **CRSwNP (IL-4, IL-13, IL-5)** | **Allergic rhinitis (IL-4, IL-13, IL-5)** |
|-------------------------------|-------------------------------|-------------------------------|
| Inflammatory cell trafficking to the tissue | Inflammatory cell trafficking to the tissue | Inflammatory cell trafficking to the tissue |
| IgE production | IgE production | IgE production |
| Goblet cell hyperplasia/mucus production | Goblet cell hyperplasia/mucus production | Goblet cell hyperplasia/mucus production |
| Barrier dysfunction | Barrier dysfunction | Barrier dysfunction |
| Tissue remodelling | Tissue remodelling | Tissue remodelling |
| Smooth muscle proliferation/contractility | Microbiome alterations | Microbiome alterations |

IL: interleukin; CRSwNP: chronic rhinosinusitis with nasal polyps.
molecules, loss of the epithelial barrier and impaired mucus clearance. The result is colonisation by bacteria and fungi and loss of barrier function and accumulation of antigens/allergens in the sinonasal cavity, which can access mucosal tissue and activate eosinophils, mast cells and other immune effector cells, as well as T- and B-cell recruitment [70]. Therefore, this defective barrier plays an important role in the initiation and maintenance of chronic rhinosinusitis and is a common feature across type 2 inflammatory diseases. Studies of epithelial barrier dysfunction in upper and lower airways have shown key pathophysiological roles of IL-4 and IL-13, contributing to both bronchial (asthma) and sinonasal (CRSwNP) epithelial barrier dysfunction through disruption of epithelial junctions and thus increasing epithelial permeability [110].
Goblet-cell hyperplasia, excess mucus production and mucociliary dysfunction are also features of type 2 inflammatory remodelling in both asthma and CRSwNP [104, 111–113].

In CRSwNP, IL-4 and IL-13 induce activation of M2-type macrophages, which contribute to the pathogenesis of CRSwNP by inducing fibrin deposition, oedematous remodelling and polyp formation, while IL-13 has additional effects on goblet cells, mucus production and nasal epithelial cell mucociliary differentiation [3, 114]. Likewise, in patients with upper airway disease such as CRSwNP, IL-13 supports alterations in nasal epithelium, inducing MUC5AC, in turn impairing ciliary function [115].

As mentioned, IL-4 and IL-13 are key and central type 2 cytokines in type 2 inflammation and have an important role to play in driving airway and tissue remodelling in type 2 inflammatory diseases of the upper and lower airways [3, 31, 91, 116–118]. Airway wall thickening in both asthma and CRSwNP is driven by overexpression of both IL-4 and IL-13, inducing fibrosis through transforming growth factor-β [119]. Type 2 inflammation is also key to the remodelling processes involved in polyp formation, with IL-4 and IL-13 causing a decrease in tight junction proteins and activation of epithelial-to-mesenchymal transition induction [3] and membrane thickening. Additionally, IL-4 and IL-13 contribute to remodelling and nasal polyp formation in CRSwNP by inducing activation of macrophages to M2 macrophages and inhibiting fibrin degradation (IL-13) [3, 114].

**Type 2 inflammation in allergic rhinitis**

The pathophysiology of allergic rhinitis is similar to that of other upper inflammatory airway diseases, such as CRSwNP. Type 2 inflammatory cells and mediators, including Th2 cells and ILC2, drive the type 2 response cascade leading to the release of further response mediators, including the interleukins IL-4, IL-13 and IL-5, and eosinophils [31]. As with CRSwNP, these type 2 inflammatory drivers result in goblet-cell hyperplasia, mucus production and barrier dysfunction. The role of IgE in allergic rhinitis is very important: on allergen contact, cross-linking IgE bound to its receptor induces mast cells to release granules and subsequently chemical mediators, resulting in inflammation [120–122].

**Other comorbidities**

Type 2 inflammation underpins multiple other comorbid diseases including atopic dermatitis, allergic bronchopulmonary aspergillosis [123], AERD, ocular diseases, eosinophilic oesophagitis and other gastrointestinal disorders, and food allergies.

Elevated IgE levels are common in patients with atopic dermatitis who have history of allergic rhinitis and asthma [124] and up to one-third of children with atopic dermatitis develop asthma [125]. Moreover, both IL-4 and IL-13 play key roles in modulation of the epidermal barrier and development of atopic dermatitis, with many children having higher levels of serum IL-13 than healthy children [126].

Allergic bronchopulmonary aspergillosis, sometimes classified as a subtype of asthma, affects approximately 5 million patients with asthma, representing an 8.4% comorbidity [123]. It is an IgE-mediated disease, with increased IgE and IgG antibodies and peripheral blood eosinophilia [6], resulting in chronic mucus hypersecretion and accelerated loss of lung function [127]. As in AERD, both upper airway pathology and lower airway pathology in NSAID-ERD patients are characterised by chronic and extensive eosinophilic mucosal inflammation related to abnormalities of both cyclo-oxygenase- and lipoxygenase-derived arachidonic acid metabolism [128]. Food allergy (e.g. eggs) could also be associated with asthma, especially in early life [129]. The predisposition for asthma in patients with food allergies is clear and should not be ignored, with preventable interactions manifesting in the form of respiratory symptoms and bronchial hyperreactivity during food-induced anaphylaxis, and severe asthma resulting from the cross-reactivity between pollen and allergens from fruits and vegetables [130].

**Biomarkers for type 2 inflammation**

The heterogeneous nature of asthma and its comorbidities requires identification of biomarkers and timely introduction of early and effective personalised medicine for those not being adequately managed by ICS and LABA alone. Inflammatory cytokines (IL-4, IL-13 and IL-5) and their receptors, among others, are important targets for treating type 2 asthma, since they promote an increase in inflammation. Fractional exhaled nitric oxide ($F_{ENO}$), thymus and activation-regulated chemokine (TARC), eotaxin, periostin, IgE and blood eosinophil counts have all emerged as predominant biomarkers for type 2 inflammatory airway diseases, providing opportunities for better disease targeting, improving patients’ health-related QoL, and reducing direct and indirect cost burdens associated with ineffective management of asthma in the long term. $F_{ENO}$ and blood eosinophil count are produced through the action of cytokine mediators [31, 100–102, 131–134]. Chemotactic biomarkers of type 2 inflammation include eotaxin-3 and TARC, which are
Recent asthma guidelines recommend the use of type 2 biomarkers to establish the cause of asthma and determine the best course of treatment [1]. The Global Initiative for Asthma (GINA) [1] defines type 2 airway inflammation when the following criteria are met: blood eosinophils ≥150 cells·µL⁻¹ and/or FeNO ≥20 ppb and/or sputum eosinophils ≥2% and/or asthma clinically allergen-driven and/or need for maintenance OCS (repeat blood eosinophils and FeNO up to three times, on lowest possible OCS dose) [1]. However, despite candidate biomarkers being identified, there are no recommendations as yet for testing in CRSwNP. Endotyping, phenotyping, treatment response and biomarkers are a rapidly evolving fields and further research is needed [2].

Management of severe asthma and other airway diseases with type 2 inflammation

Guidelines
The goals of asthma management include achieving control of symptoms and maintaining normal activity levels for physical and social development, while minimising the risk of disease exacerbation, impaired lung development, and side-effects associated with medications [1, 85, 86]. The GINA 2021 guidelines’ stepwise approach to the management of asthma (figure 2) [1] ranges from steps 1 and 2 with as-needed reliever medications (low-dose ICS-formoterol as a preferred option or a short-acting β-agonist as an alternative) and low-dose ICS as a controller, through steps 3 and 4 treatment with low- to medium-dose maintenance of ICS-formoterol or ICS/LABA, to step 5 with a high dose of dual controllers or the addition of a third controller with long-acting muscarinic antagonists and biological therapies. Low-dose OCS could be an alternative, but side-effects should be considered. Despite these comprehensive guidelines, the management of moderate and severe forms of atopic diseases such as asthma remain a challenge for physicians. It is apparent that comorbidities are important in the management of severe asthma, as they may contribute to poor disease control by both exacerbating and mimicking symptoms of asthma, resulting in overtreatment of asthma symptoms and increased costs. Given the heterogeneous pathobiology and multiple phenotypes of asthma and its associated comorbidities, there is a need for a personalised approach for the diagnosis and subsequent management of asthma. Type 2 inflammation underlies type 2 asthma and associated comorbidities, and there is a need to fully understand allergic, eosinophilic and combined phenotypes to ensure improvements in the management of this disease. Nevertheless, the key treatment objective for all patients with asthma includes full control of the disease with minimum side-effects.

Current guidelines, including those from GINA (2021) [1], the European Position Paper on Rhinosinusitis and Nasal Polyps (EPOS) (2020) [2] and the European Forum for Research and Education in Allergy and Airway Diseases (EUFOREA) (2019) [16] recognise that side-effects associated with standard of care (i.e. standard care services) should be minimised, while acknowledging the major role of type 2 inflammation in asthma and CRSwNP, as well as other inflammatory airway diseases. The GINA guidelines [1] recommend considering add-on type-2-targeted biological treatments for patients with exacerbations or poor symptom control on high-dose ICS+LABA, and who have allergic or eosinophilic biomarkers, or need maintenance OCS. These guidelines include the use of either an anti-IL-4 receptor as add-on treatment, anti-IgE or anti-IL-5 in patients with severe asthma who do not adequately respond to the standard of care. Anti-IL-4Rx agents block the signalling of both IL-4 and IL-13 [135]. The EPOS guidelines [2] also highlight the role of type 2 inflammation in CRSwNP and the impact of comorbid diseases on CRSwNP, highlighting the need to take these diseases into consideration when treating CRSwNP. Likewise, the EUFOREA [16] guidelines recommend development of a multidisciplinary integrated care pathway in daily practice where all patients with chronic rhinosinusitis receive at least one systematic assessment for asthma and allergic rhinitis, ideally using a validated questionnaire along with systematic evaluation of their upper and lower airways at every clinical visit.

Standard of care and unmet needs
The majority of type 2 inflammatory airway diseases, such as asthma and CRSwNP, remain poorly controlled with the current standard of care [48, 136]. A substantial proportion (23–32%) of asthma patients treated with ICS and LABA have been shown not to achieve GINA-defined well-controlled asthma after 1 year of ICS±LABA use [137]. Similarly, although surgical removal of nasal polyps is the standard of care in patients with severe CRSwNP, following oral or systemic corticosteroid treatment, 80% of these patients experience recurrence of polyps. The overuse of systemic corticosteroids is associated with adverse effects, including immunosuppression, weight gain, diabetes, osteoporosis, glaucoma, anxiety and depression and cardiovascular disease [138, 139].
**Asthma medications (adjust down/up/between tracks)**

**Controller and Preferred Reliever (track 1). Using ICS-formoterol as reliever reduces the risk of exacerbations compared with using a SABA reliever.**

**Controller and Alternative Reliever (track 2). Before considering a regimen with SABA reliever, check if the patient is likely to be adherent with daily controller.**

**Other controller options for either track**

---

**Assess and treat severe asthma phenotypes**

**Continue to optimise management (including inhaler technique, adherence, comorbidities)**

**Assess the severe asthma phenotype during high-dose ICS treatment (or lowest possible dose of OCS)**

---

**Investigate for comorbidities/differential diagnoses and treat/refer as appropriate**
- Consider: CBC, CRP, IgE, IgG, IgA, fungal precipitins; chest radiography and/or HRCT chest; DCC
- Skin prick testing or specific IgE for relevant allergens, if not already done
- Other directed testing (e.g. ANCA, CT sinuses, BNP, echocardiogram) based on clinical suspicion
- Consider need for social/psychological support
- Invite patient to enrol in registry (if available) or clinical trial (if appropriate)

---

**Which biologic is appropriate to start first?**

**Type 2 inflammation**

- **Blood eosinophils ≥150 cells·L⁻¹ and/or**
  - Exacerbations in last year+++
  - Blood eosinophils, e.g. 150 cells·L⁻¹ or 300 cells·L⁻¹++
  - Total serum IgE and weight within dosage range++
  - Anti-IgE?
  - Anti-IL5/5R?

**Type 2 targeted biologic for patients with exacerbations or poor symptom control on high-dose ICS-LABA, who:**
- have eosinophilic or allergic biomarkers, or
- need maintenance OCS
- Consider local payer eligibility criteria, comorbidities and predictors of response when choosing between available therapies
- Also consider cost, dosing frequency, route (i.e. or i.c.) and patient preference

**Consider add-on type 2-targeted biologic:**

**Is the patient eligible for anti-IgE for severe eosinophilic asthma?**

- **Anti-IgE**
  - What factors may predict good asthma response to anti-IgE?
  - Blood eosinophils ≥250 cells·L⁻¹++
  - FENO ≥20 ppb++
  - Allergen-driven symptoms+
  - Childhood-onset asthma+
  - exacerbations or poor control within dosage range++
  - Good asthma response to anti-IgE

**Anti-IL5/5R**

- **Is the patient eligible for anti-IL5/5R for severe eosinophilic asthma?**
- **Is the patient eligible for anti-IL5/5R for severe eosinophilic asthma?**
  - Higher blood eosinophil++
  - More exacerbations in previous year++
  - Adult-onset asthma++
  - Nasal polyposis+
  - Good asthma response to anti-IL5/5R?

---

![Diagram of asthma management framework](https://example.com/diagram.png)

**Consider add-on type 2-targeted biologic:**

**Anti-IL4R**

- **Is the patient eligible for anti-IL4R?**
  - Higher blood eosinophil+++ or FENO 525 ppb+++...or because of need for maintenance OCS?

**Consider add-on type 2-targeted biologic:**

---

**Check local eligibility criteria for specific biologic therapies as these may vary from those listed**

---

**Return to section 6a**
Standard of care treatments have nonspecific anti-inflammatory effects on a range of cell types, often targeting symptoms, but do not specifically target cytokines (IL-4, IL-13 and IL-5) involved in inflammation, and can lead to serious treatment-related adverse effects and costs [1, 2, 140]. This unmet need has led to the development of cytokine-targeted therapies and the biological-focused management of type 2 inflammatory airway diseases. Although IL-13 can be inhibited by ICS, there is a proportion of uncontrolled asthma patients who, despite treatment with high-dose ICS and systemic corticosteroids, have elevated levels of IL-13 in their sputum [141]. Hence, the IL-13 pathway has been identified as a potential therapeutic target in severe asthma and associated allergic diseases, with selective monoclonal antibody therapies being developed. There is a clear need for unified management of these type 2 inflammatory airway diseases.

**Targeted therapies**

Improved understanding of the type 2 inflammatory mediators described here has led to the development of targeted therapies for upper and lower type 2 inflammatory airway diseases, many of which are yielding promising results in difficult-to-treat asthma patients. The six biological therapies approved for asthma so far, and some other type 2 inflammatory diseases, include omalizumab (anti-IgE), mepolizumab (anti-IL-5), reslizumab (anti-IL-5), benralizumab (anti-IL-5Rx), dupilumab (anti-IL-4Rx) and tezepelumab (anti-thymic stromal lymphopoietin (TSLP)), each of these targeting specific cytokines involved in the type 2 inflammatory cascade (table 4). Omalizumab is approved as an add-on treatment for moderate-to-severe persistent allergic asthma inadequately controlled with ICS and for severe CRSwNP. Omalizumab binds to free circulating IgE [145, 146]; however, because IgE production occurs downstream of Th2 cell activation and IL-4 and IL-13 release, it can only target one feature of the type 2 inflammatory response [147–152].

Three anti-IL-5 therapies (mepolizumab, reslizumab and benralizumab) are approved as add-on agents for the treatment of severe eosinophilic asthma [143, 153–157]. Mepolizumab and reslizumab inhibit IL-5 activity by blocking the binding of IL-5 to the receptor expressed on the eosinophils cell surface, while benralizumab binds directly to IL-5Rx expressed on eosinophils and basophils. Dupilumab is a human monoclonal antibody, which binds specifically to the shared receptor component for IL-4 and IL-13, thus inhibiting the dual signalling pathways of both IL-4 and IL-13 [31]. Thus, dupilumab inhibits IL-4 signalling via the type 1 receptor and both IL-4 and IL-13 signalling through the type 2 receptor.

Each of these targeted biological agents have demonstrated clinical benefits in patients with type 2 inflammatory airway diseases. Two of three pivotal trials of omalizumab, as an add-on to high-dose ICS plus LABA, demonstrated reduced asthma exacerbations in adolescents and adults with moderate-to-severe asthma with an allergic phenotype [145]. However, omalizumab may have limited effects on lung function. Similar results were seen in two trials of mepolizumab in patients selected with raised blood eosinophil levels (Mepolizumab as Adjunctive Therapy in Patients with Severe Asthma (MENSA) and Steroid Reduction with Mepolizumab Study (SIRIUS)), which, despite not showing consistent improvement in lung function across trials, significantly reduced asthma exacerbations as well as improving QoL [158]. However, anti-IL-5 treatment was successful in the MENSA and SIRIUS trials in patients selected for raised blood eosinophil levels. Intravenous reslizumab has also demonstrated significant improvements in lung function, asthma exacerbations [159, 160] and QoL; however, reduction in OCS daily dose was not achieved with the subcutaneous formulation [159, 161]. Similar results were seen in the CALIMA and SIROCCO trials of benralizumab, with beneficial effects on exacerbations, lung function and QoL; however, these benefits were only seen consistently in patients with blood eosinophil count ≥300 cells·μL⁻¹ [162]. A recent study found a significant reduction in exacerbations and reduced need for OCS in patients following 1 year of treatment with benralizumab [163]. Clinical trials of dupilumab demonstrate reduced asthma exacerbations and produced rapid and sustained improvements in lung function, QoL and asthma control in patients with uncontrolled persistent asthma [164–167]. Moreover, dupilumab has enabled reduction in OCS use, regardless of type 2 inflammatory biomarker at baseline, while maintaining reductions in exacerbations and improvements in lung function, QoL and asthma control in a broad population of adults with severe steroid-dependent asthma [168].

**FIGURE 2** The Global Initiative for Asthma stepwise approach to control symptoms and minimise future asthma risk in adults and adolescents aged >12 years [1]. ICS: inhaled corticosteroid; SABA: short-acting β-agonist; LAMA: long-acting muscarinic antagonist; IL: interleukin; LABA: long-acting β-agonist; LTRA: leukotriene receptor antagonist; HDM: house dust mite; SLIT: sublingual allergen immunotherapy; OCS: oral corticosteroid; FeNO: exhaled nitric oxide fraction; s.c.: subcutaneous; i.v.: intravenous; CBC: complete blood count; CRP: C-reactive protein; HRCT: high-resolution computed tomography; DLCO: diffusing capacity of the lung for carbon monoxide; ANCA: antineutrophil cytoplasmic antibodies; CT: computed tomography; BNP: brain natriuretic peptide.
| TABLE 4 | Approved biological therapies for type 2 inflammatory airway diseases |
|----------------|-------------------------------------------------|
| **Omalizumab**  | **Mepolizumab**  | **Reslizumab**  | **Benralizumab**  | **Dupilumab**  | **Tezepelumab** |
| (anti-IgE)       | (anti-IL-5)       | (anti-IL-5)       | (anti-IL-5R)       | (anti-IL-4R)       | (anti-TSLP)       |
| **Approval (asthma)** | US indication: patients with moderate-to-severe persistent allergic asthma aged ≥6 years | US indication: patients with severe eosinophilic asthma aged ≥6 years | US indication: patients with severe eosinophilic asthma aged ≥6 years | US indication: patients with severe eosinophilic asthma aged ≥18 years | US indication: patients with moderate-to-severe eosinophilic asthma or OCS-dependent asthma aged ≥6 years [142] |
|                  | EMA indication: patients with severe refractory eosinophilic asthma aged ≥6 years | EMA indication: patients with severe refractory eosinophilic asthma aged ≥18 years | EMA indication: patients with severe refractory eosinophilic asthma aged ≥18 years | EMA indication: patients with severe eosinophilic asthma aged ≥12 years | EMA indication: patients with severe asthma with type 2 inflammation (elevated F_{ENO}/eosinophils) aged ≥12 years |
| **Approval (CRSwNP)** | Approved EU and US CRSwNP inadequately controlled | EMA indication: inadequately controlled severe CRSwNP | Phase 3 recruiting CRS with elevated eosinophils | Phase 3 complete severe symptomatic bilateral nasal polyps | Approved EU and US CRSwNP inadequately controlled | Phase 3 recruiting |
|                  | US indication: inadequately controlled severe CRSwNP | | | | | |
|                  | EMA indication: inadequately controlled CRSwNP [143] | | | | | |
| **Approval (COPD)** | Phase 2 withdrawn | Phase 3 complete COPD with elevated eosinophil count | Phase 3 complete COPD with exacerbation history | Phase 3 recruiting Moderate-to-Severe COPD with type 2 inflammation | Phase 2a recruiting [144] |
|                  | Lack of eligible COPD subjects with elevated IgE | Eosinophilic granulomatosis with polyangiitis | | | |
| **Approval (other)** | Chronic idiopathic urticaria | Hypereosinophilic syndrome | | | |
| **IL:** interleukin; **TSLP:** thymic stromal lymphopoietin; **CRSswNP:** chronic rhinosinusitis with nasal polyps; **US:** United States; **EMA:** European Medicines Agency; **OCS:** oral corticosteroids; **F_{ENO}:** exhaled nitric oxide fraction; **EU:** European Union; **CRS:** chronic rhinosinusitis.
In patients with comorbid CRSwNP, mepolizumab has reduced the rate of asthma exacerbations [169, 170]. Similar results have been seen with benralizumab in patients with asthma and comorbid CRSwNP [171]. In patients with eosinophilic asthma and self-reported CRSwNP, after 52 weeks’ reslizumab add-on therapy, asthma exacerbations were reduced by 83% and lung function (FEV1) improved compared with placebo. QoL and Asthma Control Questionnaire score were also reported to have improved in this population of eosinophilic asthma with nasal polyps [172, 173].

There is a comprehensive clinical trials programme of dupilumab in patients with CRSwNP, which has shown that dupilumab provides rapid and continuous improvement in clinical symptoms (e.g. nasal congestion, loss of smell and rhinorrhea), polyp size and sinus disease in patients uncontrolled on standard of care [174]. Moreover, dupilumab has been shown to reduce the need for systemic corticosteroids and/or the need for sinonasal surgery in adults with severe CRSwNP [175]. Furthermore, clinical trials of dupilumab have demonstrated improvements in patients with asthma and comorbid CRSwNP, including exacerbations, lung function, asthma control and QoL [176–178]. In addition, dupilumab has been shown to allow reduction of OCS dose in this patient cohort [179], and in patients presenting with CRSwNP and comorbid asthma [180]. Trials of each of these biologicals have presented a good and consistent safety profile in patients with type 2 inflammatory airways diseases. In conjunction with clinically meaningful improvement in symptoms, lung function and QoL, as well as reduction in corticosteroid use, biologicals represent an important advance in the management of uncontrolled asthma and comorbid type 2 inflammatory airway diseases.

With a better understanding of asthma pathophysiology, upstream targets of type 2 inflammation have been identified such as alarmins (IL-33 or TSLP) and some emerging biological therapies targeting those epithelial-derived cytokines are under investigation with a need for patients with type 2 low or non-type 2 asthma [181]. More recently, tezepelumab, a TSLP blocker, has been approved by the United States Food and Drug Administration as an add-on maintenance treatment in severe asthma [182].

Conclusions

Effective management of type 2 inflammatory airway diseases represents a major unmet need. Severe asthma continues to outpace asthma control in patients whose disease is managed by LABA and ICS, resulting in significant cost burden and impact on QoL of affected patients. Identifying individuals with comorbidities is important for adequate control of severe type 2 asthma, most notably with novel biological therapies that target the immune biomarkers, such as IL-4, IL-5 and IL-13. A substantial proportion of patients with asthma or severe CRSwNP remain suboptimally controlled with conventional therapies, highlighting the need for new therapies that target disease pathophysiology. Treatment guidelines for the management of asthma and CRSwNP are focused on improving signs and symptoms and achieving disease control. As treatment guidelines continue to acknowledge the value of, and recommend targeted therapies for, the treatment of asthma and comorbid type 2 inflammatory airway diseases, global access to these therapies becomes increasingly important to patients, clinicians, and society. There still remains a need for a unified treatment strategy for patients with coexisting type 2 inflammatory diseases.

Conflict of interest: J. Maspero reports grants and personal fees from AstraZeneca, MSD, Novartis, and Sanofi, personal fees from Uriach and Inmunotek, and grants and nonfinancial support from GSK. Y. Adir reports personal fees from Teva and Sanofi, and grants and personal fees from GSK and AstraZeneca. M. Al-Ahmad has nothing to disclose. C. Celis-Preciado reports grants and personal fees from AstraZeneca and GSK, grants from Boehringer, and personal fees from Novartis and Sanofi. F.D. Colodenco has nothing to disclose. P. Gavina-Bianchi has nothing to disclose. H. Lababidi has nothing to disclose. O. Ledanois is an employee of Sanofi. B. Mahoub has nothing to disclose. D-W. Perng has nothing to disclose. J.C. Vazquez reports personal fees from AstraZeneca, Boehringer Ingelheim and Sanofi. A. Yorgancioglu reports grants/research support from AstraZeneca, MSD, and Sanofi; honoraria/consultation fees from Abdi Ibrahim, AstraZeneca, Chiesi, DEVA, GSK, Novartis Sandoz and Sanofi; and other support from ERS, GARD, GINA, Turkish MoH and WHO.

Support statement: This publication was supported by Sanofi. Medical writing support was provided by John Clarke (Elevate Medical Affairs (part of Envision Pharma Group), Horsham, UK), contracted by Sanofi Genzyme for publication support services. Funding information for this article has been deposited with the Crossref Funder Registry.
References

1. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. 2019. https://ginasthma.org/wp-content/uploads/2019/06/GINA-2019-main-report-June-2019-wms.pdf. Date last accessed: January 2021.

2. Fokkens WJ, Lund VJ, Hopkins C, et al. European position paper on rhinosinusitis and nasal polyposis 2020. Rhinology 2020; 58: Suppl. S29, 1–464.

3. Schleimer RP. Immunopathogenesis of chronic rhinosinusitis and nasal polyposis. Annu Rev Pathol 2017; 12: 331–357.

4. Pinart M, Benet M, Annesi-Maesano I, et al. Comorbidity of eczema, rhinitis, and asthma in IgE-sensitised and non-IgE-sensitised children in MeDALL: a population-based cohort study. Lancet Respir Med 2014; 2: 131–140.

5. Lee LK, Obi E, Paknis B, et al. Asthma control and disease burden in patients with asthma and allergic comorbidities. J Asthma 2018; 55: 208–219.

6. Porsbjerg C, Menzies-Gow A. Co-morbidities in severe asthma: clinical impact and management. Respir Med 2017; 22: 651–661.

7. Kauppi P, Linna M, Jantunen J, et al. Chronic comorbidities contribute to the burden and costs of persistent asthma. Mediators Inflamm 2015; 2015: 819194.

8. Godard P, Chanez P, Siraudin L, et al. Costs of asthma are correlated with severity: a 1-yr prospective study. Eur Respir J 2002; 19: 61–67.

9. Hernandez G, Dima AL, Pont A, et al. Impact of asthma on women and men: comparison with the general population using the EQ-5D-5L questionnaire. PLoS One 2018; 13: e0202624.

10. Kim KH, Jahan SA, Kabir E. A review on human health perspective of air pollution with respect to allergies and asthma. Environ Int 2013; 59: 41–52.

11. Ali FR. Does this patient have atopic asthma? Clin Med 2011; 11: 376–380.

12. Adams OJ, von Gunten S. Recent advances in experimental allergy. Int Arch Allergy Immunol 2018; 177: 281–289.

13. Center for Disease Control. Most Recent Asthma Data. www.cdc.gov/asthma/most_recent_data.htm/ Date last accessed: January 2021.

14. Hastan D, Fokkens WJ, Bachert C, et al. Chronic rhinosinusitis in Europe – an underestimated disease. A GA²LEN study. Allergy 2011; 66: 1216–1223.

15. GBD 2016 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet 2017; 390: 1219–1259.

16. Fokkens WJ, Lund V, Bachert C, et al. EUFOREA consensus on biologics for CRSwNP with or without asthma. Allergy 2019; 74: 2312–2319.

17. Casanova C, Celli BR, de-Torres JP, et al. Prevalence of persistent blood eosinophilia: relation to outcomes in patients with COPD. Eur Respir J 2017; 50: 1701162.

18. Singh D, Kolsum U, Brightling CE, et al. Eosinophilic inflammation in COPD: prevalence and clinical characteristics. Eur Respir J 2014; 44: 1697–1700.

19. European Academy of Allergy and Clinical Immunology (EAACI). EAACI Global Atlas of Allergic Rhinitis and Chronic Rhinosinusitis. 2015. Available from: https://medialibrary.eaaci.org/mediatheque/media.aspx?mediaid=60233&channel=8518

20. Corren J, Lemanske RF, Hanania NA, et al. Lebrikizumab treatment in adults with asthma. N Engl J Med 2011; 365: 1088–1098.

21. Schleich F, Brusselle G, Louis R, et al. Heterogeneity of phenotypes in severe asthmatics. The Belgian Severe Asthma Registry (BSAR). Respir Med 2014; 108: 1723–1732.

22. Peters MC, Mekonnen ZK, Yuan S, et al. Measures of gene expression in sputum cells can identify T\textsubscript{h}2-high and T\textsubscript{h}2-low subtypes of asthma. J Allergy Clin Immunol 2014; 133: 388–394.

23. Kim DW, Cho SH. Emerging endotypes of chronic rhinosinusitis and its application to precision medicine. Allergy Asthma Immunol Res 2017; 9: 299–306.

24. Bachert C, Pauwankar R, Zhang L, et al. ICON: chronic rhinosinusitis. World Allergy Organ J 2014; 7: 25.

25. Delemarre T, Holtappels G, De Ruysch N, et al. Type 2 inflammation in chronic rhinosinusitis without nasal polyps: another relevant endotype. J Allergy Clin Immunol 2020; 146: 337–343.

26. Khan A, Vandeplas G, Huynh TMT, et al. The Global Allergy and Asthma European Network (GALEN) rhinosinusitis cohort: a large European cross-sectional study of chronic rhinosinusitis patients with and without nasal polyps. Rhinology 2019; 57: 32–42.

27. Bousquet J, Khaltavaev N, Cruz AA, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA²LEN and AllerGen). Allergy 2008; 63: Suppl. 86, 8–160.

28. Mindus S, Malinovschi A, Ekerljung L, et al. Asthma and COPD overlap (ACO) is related to a high burden of sleep disturbance and respiratory symptoms: results from the RHINE and Swedish GA²LEN surveys. PLoS One 2018; 13: e0195055.
14

In addition to the previous references, we have included:

29 White AA, Stevenson DD. Aspirin-exacerbated respiratory disease. N Engl J Med 2018; 379: 1060–1070.
30 Shaw DE, Sousa AR, Fowler SJ, et al. Clinical and inflammatory characteristics of the European U-BIOPRED adult severe asthma cohort. Eur Respir J 2015; 46: 1308–1321.
31 Gandhi NA, Bennett BL, Graham NM, et al. Targeting key proximal drivers of type 2 inflammation in disease. Nat Rev Drug Discov 2016; 15: 35–50.
32 Heffler E, Blasi F, Latorre M, et al. The Severe Asthma Network in Italy: findings and perspectives. J Allergy Clin Immunol Pract 2019; 7: 1462–1468.
33 Maio S, Baldacci S, Bresciani M, et al. RitA: the Italian severe/uncontrolled asthma registry. Allergy 2018; 73: 683–695.
34 Micheletto C, Visconti M, Trevisan F, et al. The prevalence of nasal polyps and the corresponding urinary LTE4 levels in severe compared to mild and moderate asthma. Eur Ann Allergy Clin Immunol 2010; 42: 120–124.
35 Miravitlles M, Alvarez-Gutierrez FJ, Calle M, et al. Algorithm for identification of asthma-COPD overlap: consensus between the Spanish COPD and asthma guidelines. Eur Respir J 2017; 49: 170068.
36 Toledo-Pons N, van Boven JFM, Roman-Rodríguez M, et al. ACO: time to move from the description of different phenotypes to the treatable traits. PLoS One 2019; 14: e0210915.
37 Licari A, Castagnoli R, Denicolò CF, et al. The nose and the lung: united airway disease? Front Pediatr 2017; 5: 44.
38 Sahay S, Gera K, Bhargava SK, et al. Occurrence and impact of sinusitis in patients with asthma and/or allergic rhinitis. J Asthma 2016; 53: 635–643.
39 Jackson D, Aljamil N, Roxas C, et al. The ‘T2-low’ asthma phenotype: could it just be T2-high asthma treated with corticosteroids? Thorax 2018; 73: A124–A125.
40 Kato A, Klingler AI, Stevens WW, et al. Heterogenous inflammation in chronic rhinosinusitis without nasal polyps. J Allergy Clin Immunol 2016; 137: AB285.
41 Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. 2019. https://goldcopd.org/wp-content/uploads/2018/11/GOLD-2019-v1.7-FINAL-14Nov2018-WMS.pdf Date last accessed: January 2021.
42 Håkansson K, Konge L, Thomsen SF, et al. Sinonasal inflammation in COPD: a systematic review. Eur Respir J 2013; 42: 1402–1411.
43 Øie MR, Dahlseth SB, Sue-Chu M, et al. Rhinosinusitis without nasal polyps in COPD. ERJ Open Res 2020; 6: 00015-2020.
44 Dean BB, Calimlim BM, Kindermann SL, et al. The impact of uncontrolled asthma on absenteeism and health-related quality of life. J Asthma 2009; 46: 861–866.
45 Sanz de Burgoa V, Rejas J. Self-perceived sleep quality and quantity in adults with asthma: findings from the CosteAsma study. J Investig Allergol Clin Immunol 2016; 26: 256–262.
46 Serrano E, Neukirch F, Pribil C, et al. Nasal polyposis in France: impact on sleep and quality of life. J Laryngol Otol 2005; 119: 543–549.
47 Radenne F, Lamblin C, Vandezande LM, et al. Quality of life in nasal polyposis. J Allergy Clin Immunol 1999; 104: 79–84.
48 Price D, Fletcher M, van der Molen T. Asthma control and management in 8,000 European patients: the REcognise Asthma and Link to Symptoms and Experience (REALISE) survey. NPJ Prim Care Respir Med 2014; 24: 14009.
49 Sullivan PW, Ghushchyan VH, Globe G, et al. Oral corticosteroid exposure and adverse effects in asthmatic patients. J Allergy Clin Immunol 2018; 141: 110–116.
50 Boulet LP. Influence of comorbid conditions on asthma. Eur Respir J 2009; 33: 897–906.
51 Ponte EV, Franco R, Nascimento HF, et al. Lack of control of severe asthma is associated with co-existence of moderate-to-severe rhinitis. Allergy 2008; 63: 564–569.
52 Staaliniene J, Vaitkus S, Japertiene LM, et al. Association of chronic rhinosinusitis with nasal polyps and asthma: clinical and radiological features, allergy and inflammation markers. Medicina 2008; 44: 257–265.
53 Stevens WW, Peters AT, Hirsch AG, et al. Clinical characteristics of patients with chronic rhinosinusitis with nasal polyps, asthma, and aspirin-exacerbated respiratory disease. J Allergy Clin Immunol Pract 2017; 5: 1061–1070.
54 Vietri J, Burslem K, Su J. Poor asthma control among US workers: health-related quality of life, work impairment, and health care use. J Occup Environ Med 2014; 56: 425–430.
55 Williams SA, Wagner S, Kannan H, et al. The association between asthma control and health care utilization, work productivity loss and health-related quality of life. J Occup Environ Med 2009; 51: 780–785.
56 Hossny E, Caraballo L, Casale T, et al. Severe asthma and quality of life. World Allergy Organ J 2017; 10: 28.
57 ten Brinke A, Sterk PJJ, Mascllee AA, et al. Risk factors of frequent exacerbations in difficult-to-treat asthma. Eur Respir J 2005; 26: 812–818.
58 Chung KF, Wenzel SE, Brozek JL, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J 2014; 43: 343–373.
Tay TR, Hew M. Comorbid “treatable traits” in difficult asthma: current evidence and clinical evaluation. Allergy 2018; 73: 1369–1382.

Auckley D, Moollem M, Shamam Z, et al. Findings of a Berlin Questionnaire survey: comparison between patients seen in an asthma clinic versus internal medicine clinic. Sleep Med 2008; 9: 494–499.

de Carvalho-Pinto RM, Cukier A, Angelini L, et al. Clinical characteristics and possible phenotypes of an adult severe asthma population. Respir Med 2012; 106: 47–56.

Moore WC, Bleecker ER, Curran-Evenett D, et al. Characterization of the severe asthma phenotype by the National Heart, Lung, and Blood Institute’s Severe Asthma Research Program. J Allergy Clin Immunol 2007; 119: 405–413.

Moore WC, Meyers DA, Wenzel SE, et al. Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program. Am J Respir Crit Care Med 2010; 181: 315–323.

Stanton AE, Vaughn P, Carter R, et al. An observational investigation of dysfunctional breathing and breathing control therapy in a problem asthma clinic. J Asthma 2008; 45: 758–765.

Yelken K, Yilmaz A, Guven M, et al. Paradoxical vocal fold motion dysfunction in asthma patients. Respiratory 2009; 14: 729–733.

Ek A, Middelveld RJ, Bertilsson H, et al. Chronic rhinosinusitis in asthma is a negative predictor of quality of life: results from the Swedish GA²LEN survey. Allergy 2013; 68: 1314–1321.

Liou A, Grubb JR, Schechtman KB, et al. Causal and contributive factors to asthma severity and patterns of medication use in patients seeking specialized asthma care. Chest 2003; 124: 1781–1788.

ten Brinke A, Grootendorst DC, Schmidt JT, et al. Chronic sinusitis in severe asthma is related to sputum eosinophilia. J Allergy Clin Immunol 2002; 109: 621–626.

Ceylan E, Gencer M, San I. Nasal polyps and the severity of asthma. Respir Med 2007; 12: 272–276.

Hulse KE. Immune mechanisms of chronic rhinosinusitis. Curr Allergy Asthma Rep 2016; 16: 1.

Bilodeau L, Boulay ME, Prince P, et al. Comparative clinical and airway inflammatory features of asthmatics with or without polyps. Rhinology 2010; 48: 420–425.

Vandenplas O, Dramai M, Joos G, et al. The impact of concomitant rhinitis on asthma-related quality of life and asthma control. Allergy 2010; 65: 1290–1297.

Bassiouni A, Wormald PJ. Role of frontal sinus surgery in nasal polyp recurrence. Laryngoscope 2013; 123: 36–41.

Coumou H, Westerhof GA, de Nijs SB, et al. Predictors of accelerated decline in lung function in adult-onset asthma. Eur Respir J 2018; 51: 1701785.

Blakely JD, Price DB, Pizzichini E, et al. Identifying risk of future asthma attacks using UK medical record data: a Respiratory Effectiveness Group initiative. J Allergy Clin Immunol Pract 2017; 5: 1015–1024.

Braido F, Baiardi I, Ghiglione V, et al. Sleep disturbances and asthma control: a real life study. Asian Pac J Allergy Immunol 2009; 27: 27–33.

Alobid I, Benitez P, Bernal-Sprekelsen M, et al. Nasal polyposis and its impact on quality of life: comparison between the effects of medical and surgical treatments. Allergy 2005; 60: 452–458.

Alobid I, Benitez P, Valero A, et al. The impact of atopy, sinus opacification, and nasal patency on quality of life in patients with severe nasal polyposis. Otolaryngol Head Neck Surg 2006; 134: 609–612.

Demol P, Arunziana K, Gubba E, et al. Repeated cross-sectional survey of patient-reported asthma control in Europe in the past 5 years. Eur Respir Rev 2012; 21: 66–74.

Lange P, Colak Y, Ingebretsen TS, et al. Long-term prognosis of asthma, chronic obstructive pulmonary disease, and asthma-chronic obstructive pulmonary disease overlap in the Copenhagen City Heart study: a prospective population-based analysis. Lancet Respir Med 2016; 4: 454–462.

Rudnik L, Soler ZM. Medical therapies for adult chronic sinusitis: a systematic review. JAMA 2015; 314: 926–939.

Cooper V, Metcalfe L, Versnel J, et al. Patient-reported side effects, concerns and adherence to corticosteroid treatment for asthma, and comparison with physician estimates of side-effect prevalence: a UK-wide, cross-sectional study. NPJ Prim Care Respir Med 2015; 25: 15062.

Canonica GW, Colombo GL, Bruno GM, et al. Shadow cost of oral corticosteroids-related adverse events: a pharmacoeconomic evaluation applied to real-life data from the Severe Asthma Network in Italy (SANI) registry. World Allergy Organ J 2019; 12: 100007.

Bhattacharyya N, Villeneuve S, Joish VN, et al. Cost burden and resource utilization in patients with chronic rhinosinusitis and nasal polyps. Laryngoscope 2019; 129: 1969–1975.
Chung KF. Targeting the interleukin pathway in the treatment of asthma. *Lancet* 2015; 386: 1086–1096.

Fahy JV. Type 2 inflammation in asthma – present in most, absent in many. *Nat Rev Immunol* 2015; 15: 57–65.

Gandhi NA, Pirozzi G, Graham NMH. Commonality of the IL-4/IL-13 pathway in atopic diseases. *Expert Rev Clin Immunol* 2017; 13: 425–437.

Robinson D, Humbert M, Buhi R, et al. Revisiting type 2-high and type 2-low airway inflammation in asthma: current knowledge and therapeutic implications. *Clin Exp ALLERGY* 2017; 47: 161–175.

Corren J. Role of interleukin-13 in asthma. *Curr Allergy Asthma Rep* 2013; 13: 415–420.

Fulkerson PC, Rothenberg ME. Targeting eosinophils in allergy, inflammation and beyond. *Nat Rev Drug Discov* 2013; 12: 117–129.

Le Floch A, Allinne J, Nagashima K, et al. Dual blockade of IL-4 and IL-13 with dupilumab, an IL-4Rx antibody, is required to broadly inhibit type 2 inflammation. *Allergy* 2020; 75: 1188–1204.

Kato A. Immunopathology of chronic rhinosinusitis. *Allergol Int* 2015; 64: 121–130.

Ramanathan M Jr, Lee WK, Spannhake EW, et al. Th2 cytokines associated with chronic rhinosinusitis with polyps down-regulate the antimicrobial immune function of human sinonasal epithelial cells. *Am J Rhinol* 2008; 22: 115–121.

Wise SK, Laury AM, Katz EH, et al. Interleukin-4 and interleukin-13 compromise the sinonasal epithelial barrier and perturb intercellular junction protein expression. *Int Forum Allergy Rhinol* 2014; 4: 361–370.

Ahern S, Cervin A. Inflammation and endotyping in chronic rhinosinusitis – a paradigm shift. *Medicina* 2019; 55: 95.

Kato A. Group 2 innate lymphoid cells in airway diseases. *Chest* 2019; 156: 141–149.

Naik SR, Wala SM. Inflammation, allergy and asthma, complex immune origin diseases. *J Allergy Clin Immunol* 2006; 368: 780–793.

Lee CG, Homer RJ, Zhu Z, et al. Interleukin-13 induces tissue fibrosis by selectively stimulating and activating transforming growth factor β1. *J Exp Med* 2001; 194: 809–821.

Verbruggen K, Van Cauwenberge P, Bachert C. Anti-IgE for the treatment of allergic rhinitis – and eventually nasal polyps? *Int Arch Allergy Immunol* 2009; 148: 87–98.

Amin K. The role of mast cells in allergic inflammation. *Respir Med* 2012; 106: 9–14.
122 Poole JA, Rosenwasser LJ. The role of immunoglobulin E and immune inflammation: implications in allergic rhinitis. *Curr Allergy Asthma Rep* 2005; 5: 252–258.

123 Agarwal R, Chakrabarti A, Shah A, et al. Allergic bronchopulmonary aspergillosis: review of literature and proposal of new diagnostic and classification criteria. *Clin Exp Allergy* 2013; 43: 850–873.

124 Bantz SK, Zhu Z, Zheng T. The atopic march: progression from atopic dermatitis to allergic rhinitis and asthma. *J Clin Cell Immunol* 2014; 5: 202.

125 van der Hulst AE, Klip H, Brand PL. Risk of developing asthma in young children with atopic eczema: a systematic review. *J Allergy Clin Immunol* 2007; 120: 565–569.

126 Cai F, Hornauer H, Peng K, et al. Bioanalytical challenges and improved detection of circulating levels of IL-13. *Bioanalysis* 2016; 8: 323–332.

127 Greenberger PA, Bush RK, Demain JG, et al. Oral corticosteroid-sparing effects of inhaled corticosteroids in the treatment of persistent and acute asthma. *Ann Allergy Asthma Immunol* 2004; 92: 512–522.

128 Haigentz ML, Agache I, Bavbek S, et al. Cytokines in chronic rhinosinusitis. Role in eosinophilia and aspirin-exacerbated respiratory disease (N-ERD) – a EAACI position paper. *Allergy* 2019; 74: 28–39.

129 Tariq SM, Matthews SM, Hakim EA, et al. Egg allergy in infancy predicts respiratory allergic disease by 4 years of age. *Pediatr Allergy Immunol* 2000; 11: 162–167.

130 Emons JAM, Gerth van Wijk R. Food allergy and asthma: is there a link? *Curr Treat Options Allergy* 2018; 5: 436–444.

131 Hulse KE, Stevens WW, Tan BK, et al. Pathogenesis of nasal polyposis. *Clin Exp Allergy* 2015; 45: 328–346.

132 Stevens WW, Ocampo CJ, Berdnikovs S, et al. Cytokines in chronic rhinosinusitis. Role in eosinophilia and aspirin-exacerbated respiratory disease. *Am J Respir Crit Care Med* 2015; 192: 682–694.

133 Zhai GT, Li JX, Zhang XH, et al. Gaining Optimal Asthma Control study. *Am J Respir Crit Care Med* 2004; 170: 836–844.

134 Gause WC, Wynn TA, Allen JE. Type 2 immunity and wound healing: evolutionary refinement of adaptive immunity by helminths. *Nat Rev Immunol* 2013; 13: 607–614.

135 Bagnasco D, Ferrando M, Varricchi G, et al. The atopic march: progression from atopic dermatitis to allergic rhinitis and asthma. *J Clin Cell Immunol* 2014; 5: 202.

136 van der Veen J, Demain JG, et al. Allergic bronchopulmonary aspergillosis. *J Allergy Clin Immunol Pract* 2014; 2: 703–708.

137 Defrance T, Carayon P, Billian G, et al. Interleukin-4 deficient mice. *Defrance T, Carayon P, Billian G, et al.* *J Allergy Clin Immunol* 2008; 121: 685–691.

138 Santof. Dupixent (Dupilumab) Summary of Product Characteristics. 2021. https://www.ema.europa.eu/en/documents/product-information/dupixent-epar-product-information_en.pdf Date last accessed: 1 February 2022.

139 AstraZeneca. A Randomized, Double-blind, Placebo-controlled, Parallel Group, Multicenter Phase 2a Study to Explore the Efficacy and Safety of Tezepelumab in Patients With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) (COURSE). https://clinicaltrials.gov/ct2/show/NCT04039113?draw=2&rank=1 Date last accessed: 1 February 2022.

140 Novartis. Xolair (Omalizumab) Summary of Product Characteristics. 2019. www.ema.europa.eu/en/documents/product-information/xolair-epar-product-information_en.pdf Date last accessed: January 2021.

141 Emons JAM, Gerth van Wijk R. Food allergy and asthma: is there a link? *Curr Treat Options Allergy* 2018; 5: 436–444.

141 AstraZeneca. A Randomized, Double-blind, Placebo-controlled, Parallel Group, Multicenter Phase 2a Study to Explore the Efficacy and Safety of Tezepelumab in Patients With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) (COURSE). https://clinicaltrials.gov/ct2/show/NCT04039113?draw=2&rank=1 Date last accessed: 1 February 2022.

142 GlaxoSmithKline. Nucala (Mepolizumab) Summary of Product Characteristics. September 2019. https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Nucala/pdf/NUCALA-PI-PIL-IFU-COMBINED. PDF Date last accessed: 1 February 2022.

143 SANOFI. Dupixent (Dupilumab) Summary of Product Characteristics. 2021. https://www.ema.europa.eu/en/documents/product-information/dupixent-epar-product-information_en.pdf Date last accessed: 1 February 2022.

144 Allergy. *In: Holgate ST, Church MK, Broide DH, et al., eds. Allergy. 4th Edn. New York, Elsevier Saunders, 2012; pp. 1–32.

145 Oettgen H, Broide DH. Introduction to mechanisms of allergic disease. *In: Holgate ST, Church MK, Broide DH, et al., eds. Allergy. 4th Edn. New York, Elsevier Saunders, 2012; pp. 1–32.

146 DeFrance T, Carayon P, Billian G, et al. Interleukin 13 is a B cell stimulating factor. *J Exp Med* 1994; 179: 135–143.

147 Novartis. Xolair (Omalizumab) Summary of Product Characteristics. 2019. www.ema.europa.eu/en/documents/product-information/xolair-epar-product-information_en.pdf Date last accessed: January 2021.

148 Kühn R, Rajewsky K, Müller W. Generation and analysis of interleukin-4 deficient mice. *Science* 1991; 254: 707–710.

149 Pène J, Rousset F, Brière F, et al. IgE production by normal human lymphocytes is induced by interleukin 4 and suppressed by interferons γ and α and prostaglandin E2. *Proc Natl Acad Sci USA* 1988; 85: 6880–6884.

150 Punnonen J, Aversa G, Cocks BG, et al. Interleukin 13 induces interleukin 4-independent IgG4 and IgE synthesis and CD23 expression by human B cells. *Proc Natl Acad Sci USA* 1993; 90: 3730–3734.
Bachert C, Desrosiers M, Mullol J, et al. A randomized phase 3 study, Sinus-52, evaluating the efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps. J Allergy Clin Immunol 2019; 143: AB433.

Pavord ID, Ford L, Sher L, et al. Dupilumab efficacy in asthma patients with comorbid chronic rhinosinusitis or nasal polyposis (CRS/NP) in LIBERTY ASTHMA QUEST. Eur Respir J 2018; 52: Suppl. 62, OA1651.

Corren J, Castro M, Maspero JF, et al. Dupilumab improves asthma-related patient reported outcomes in asthma patients with chronic rhinosinusitis or nasal polyposis (CRS/NP) in LIBERTY ASTHMA QUEST. Eur Respir J 2018; 52: Suppl. 62, PA1124.

Busse W, Maspero JF, Katelaris CH, et al. Dupilumab improves SNOT-22 scores in asthma patients with chronic rhinosinusitis or nasal polyposis (CRS/NP) in LIBERTY ASTHMA QUEST. Eur Respir J 2018; 52: Suppl. 62, PA1125.

Rabe K, Castro M, Nair P, et al. Dupilumab reduces oral corticosteroid (OCS) use and severe exacerbations, and improves FEV1 in OCS-dependent, severe asthma with comorbid chronic rhinosinusitis with and without nasal polyposis. Allergy 2019; 74: Suppl. 106, OA0055.

Cho S, Maspero JF, Canonica GW, et al. Dupilumab improves upper and lower airway outcome measures in patients with severe chronic rhinosinusitis with nasal polypos and comorbid asthma: pooled results from the SINUS-24 and SINUS-52 phase 3 studies. Am J Respir Crit Care Med 2019; 199: A7356.

Assaf SM, Hanania NA. Biological treatments for severe asthma. Curr Opin Allergy Clin Immunol 2019; 19: 379–386.

AstraZeneca. TEZSPIRE (Tezepelumab-Ekko) Summary of Product Characteristics. 2021. www.accessdata.fda.gov/drugsatfda_docs/label/2021/761224s000lbl.pdf Date last accessed: 1 February 2021.